Media Coverage

James Foster Interview on Mad Money with Jim Cramer


In an exclusive interview, CNBC’s Jim Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories, about the Company’s growth plans, drug prices and the future of cancer research.

Charles River Laboratories is first CRO to join U.K.-based research consortium


Charles River Laboratories is the first full-service contract research organization (CRO) to join the U.K.-based, international Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute and Consortium is a collaborative matchmaking service established in 2015 that connects academic research centers, pharmaceutical companies and the industry’s leading scientists in an effort to accelerate research and improve outcomes for patients.

Charles River CEO: 'Companies that don’t grow, die'


For James Foster, CEO of what is already the second largest Massachusetts-based company in the drug development industry by headcount, Charles River Laboratories, continued growth is a necessity. That mentality has spurred seven acquisitions since 2014.

Five Tips to Ensure Your Biomarker Passes Muster


Widespread adoption of biomarkers has been impeded by a lack of consistent validation methodology and an unclear regulatory environment. If a biomarker is being used to determine the safety and/or effectiveness of a drug, it should be validated rigorously. Here are five key points to consider.

The Growing Role of CROs in Cancer Drug Development


Although cancer’s status as the leading therapeutic area for drug candidates looks set to remain unrivaled for the foreseeable future, the emphasis on each stage of drug discovery and development tends to fluctuate according to each drug maker’s pipeline. Aidan Synnott from Charles River discusses preclinical cancer drug development in Drug Discovery & Development.

If I Knew Then... James C. Foster


Business isn't always perfect. In Crain's "If I Knew Then…" column, Jim Foster discusses what he's learned from his mistakes, including the importance of working with great people.

2016 New Investigator: Hua Wang


Hua Wang was recently nominated for Bioanalysis Zone's New Investigator Award. Hua is a member of our team in Ohio, and joined Charles River as part of WIL Research this year. He is an outstanding scientist who has contributed significantly to a variety of bioanalysis projects to support drug development programs.

Charles River Mulls Moonshots and Mouse Models


Charles River is conducting new studies using animal models to give insight into therapeutic strategies where pharma companies expect to see the most success. These advances in research models are making “moonshots” a reality for cancer patients. Dr. Joseph Murphy from Charles River discusses more on

Outsourcing Biosimilars Development


A rapid increase in the number of companies working on development and registration of biosimilars has created a significant market for outsourced services specific to these products. Biosimilar developers turn to contract organizations when they lack either the internal capability or capacity for conducting certain work as well as when they require additional resources to bring products to market rapidly.

Charles River: 2016 to Be ‘Robust Year’


After reporting a successful start to FY16, Charles River expects continued success this year driven by customer demand and enhanced strategic partnerships, including expansion of its early stage portfolio.

Displaying results 1-10 (of 72)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8  >  >|